These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25219748)

  • 1. Lupus erythematosus-like skin eruption after vemurafenib therapy.
    Reinholz M; Berking C; Hermans C; Ruzicka T; Braun-Falco M
    J Am Acad Dermatol; 2014 Oct; 71(4):e159-60. PubMed ID: 25219748
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous side effects of vemurafenib: a case report and discussion.
    Shea SM; Boyd K; Patterson J
    Wien Med Wochenschr; 2013 Aug; 163(15-16):376-9. PubMed ID: 23824179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
    Dabner M; Harvey NT; Soma A; Wood BA
    Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
    [No Abstract]   [Full Text] [Related]  

  • 4. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
    Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
    J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
    Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
    JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vemurafenib-induced granulomatous hepatitis.
    Spengler EK; Kleiner DE; Fontana RJ
    Hepatology; 2017 Feb; 65(2):745-748. PubMed ID: 27335285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib-induced granuloma annulare.
    Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
    [No Abstract]   [Full Text] [Related]  

  • 8. Complete pathologic response after neoadjuvant treatment with vemurafenib for malignant melanoma.
    Kaidar-Person O; Eran A; Bar-Sela G
    J Am Acad Dermatol; 2014 Feb; 70(2):e39-41. PubMed ID: 24438978
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
    Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
    J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 11. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.
    Boyd KP; Vincent B; Andea A; Conry RM; Hughey LC
    J Am Acad Dermatol; 2012 Dec; 67(6):1375-9. PubMed ID: 22940405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption.
    Gupta M; Huang V; Linette G; Cornelius L
    Arch Dermatol; 2012 Aug; 148(8):966-8. PubMed ID: 22911209
    [No Abstract]   [Full Text] [Related]  

  • 13. Four times repeated isolated limb infusion with melphalan-controlled locoregional disease in the patient with melanoma of the leg.
    El Halabi H; Hijaz F; Gushchin V
    Am Surg; 2012 Dec; 78(12):E504-5. PubMed ID: 23265100
    [No Abstract]   [Full Text] [Related]  

  • 14. Spindle cell squamous carcinoma during BRAF inhibitor therapy for advanced melanoma: an aggressive secondary neoplasm of undetermined biologic potential.
    Cohen DN; Lumbang WA; Boyd AS; Sosman JA; Zwerner JP
    JAMA Dermatol; 2014 May; 150(5):575-7. PubMed ID: 24577111
    [No Abstract]   [Full Text] [Related]  

  • 15. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eccrine squamous syringometaplasia associated with vemurafenib therapy.
    Story SG; Beschloss JK; Dolan CK; Thomas BC
    J Am Acad Dermatol; 2012 Nov; 67(5):e208-10. PubMed ID: 23062917
    [No Abstract]   [Full Text] [Related]  

  • 17. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib-induced eccrine squamous syringometaplasia.
    Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
    Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
    Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
    Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.